These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Synthesis of Novel Potent Archazolids: Pharmacology of an Emerging Class of Anticancer Drugs. Scheeff S; Rivière S; Ruiz J; Abdelrahman A; Schulz-Fincke AC; Köse M; Tiburcy F; Wieczorek H; Gütschow M; Müller CE; Menche D J Med Chem; 2020 Feb; 63(4):1684-1698. PubMed ID: 31990540 [TBL] [Abstract][Full Text] [Related]
8. Archazolid and apicularen: novel specific V-ATPase inhibitors. Huss M; Sasse F; Kunze B; Jansen R; Steinmetz H; Ingenhorst G; Zeeck A; Wieczorek H BMC Biochem; 2005 Aug; 6():13. PubMed ID: 16080788 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and activity of the archazolid western hemisphere. Tran AB; Melly GC; Doucette R; Ashcraft B; Sebren LJ; Havko N; Young JC; O'Neil GW Org Biomol Chem; 2011 Oct; 9(22):7671-4. PubMed ID: 21931924 [TBL] [Abstract][Full Text] [Related]
10. Total Synthesis of Archazolid F. Scheeff S; Menche D Org Lett; 2019 Jan; 21(1):271-274. PubMed ID: 30548075 [TBL] [Abstract][Full Text] [Related]
11. Modular total synthesis of archazolid A and B. Menche D; Hassfeld J; Li J; Mayer K; Rudolph S J Org Chem; 2009 Oct; 74(19):7220-9. PubMed ID: 19739663 [TBL] [Abstract][Full Text] [Related]
12. Resistance mechanisms of cancer cells to the novel vacuolar H(+)-ATPase inhibitor archazolid B. Hamm R; Sugimoto Y; Steinmetz H; Efferth T Invest New Drugs; 2014 Oct; 32(5):893-903. PubMed ID: 25065443 [TBL] [Abstract][Full Text] [Related]
13. V-ATPase inhibition by archazolid leads to lysosomal dysfunction resulting in impaired cathepsin B activation in vivo. Kubisch R; Fröhlich T; Arnold GJ; Schreiner L; von Schwarzenberg K; Roidl A; Vollmar AM; Wagner E Int J Cancer; 2014 May; 134(10):2478-88. PubMed ID: 24166050 [TBL] [Abstract][Full Text] [Related]
14. Anti-leukemic effects of the V-ATPase inhibitor Archazolid A. Zhang S; Schneider LS; Vick B; Grunert M; Jeremias I; Menche D; Müller R; Vollmar AM; Liebl J Oncotarget; 2015 Dec; 6(41):43508-28. PubMed ID: 26496038 [TBL] [Abstract][Full Text] [Related]
15. EPR Studies of V-ATPase with Spin-Labeled Inhibitors DCC and Archazolid: Interaction Dynamics with Proton Translocating Subunit c. Gölz JP; Bockelmann S; Mayer K; Steinhoff HJ; Wieczorek H; Huss M; Klare JP; Menche D ChemMedChem; 2016 Feb; 11(4):420-8. PubMed ID: 26662886 [TBL] [Abstract][Full Text] [Related]
16. Total synthesis of archazolid A. Menche D; Hassfeld J; Li J; Rudolph S J Am Chem Soc; 2007 May; 129(19):6100-1. PubMed ID: 17455939 [No Abstract] [Full Text] [Related]
17. Design, Synthesis and Biological Evaluation of Highly Potent Simplified Archazolids. Rivière S; Vielmuth C; Ennenbach C; Abdelrahman A; Lemke C; Gütschow M; Müller CE; Menche D ChemMedChem; 2020 Jul; 15(14):1348-1363. PubMed ID: 32363789 [TBL] [Abstract][Full Text] [Related]
18. Archazolid A binds to the equatorial region of the c-ring of the vacuolar H+-ATPase. Bockelmann S; Menche D; Rudolph S; Bender T; Grond S; von Zezschwitz P; Muench SP; Wieczorek H; Huss M J Biol Chem; 2010 Dec; 285(49):38304-14. PubMed ID: 20884613 [TBL] [Abstract][Full Text] [Related]